TGX-007

Trogenix (LSE: TRO) reported breakthrough preclinical results for its Synthetic Super-Enhancer (SSE) gene therapy in aggressive brain cancer. Data published in Nature demonstrated that a single dose achieved complete tumor elimination in 83% of glioblastoma models with no recurrence over 11 months, as per the company’s announcement. In preclinical models, SSEs delivered via adeno-associated virus vectors produced tumour regression within one to two weeks of a single treatment dose, with complete tumour clearance occurring over the subsequent two to three weeks in 83% of cases. Treated animals showed no detectable tumour formation even after re-challenge, and no toxicity was reported across the 11-month observation window. The SSEs are engineered to activate SOX2 and SOX9-driven gene networks selectively in glioblastoma stem cells, carrying two payloads: HSV-TK, a cytotoxic agent for direct tumour killing, and IL-12, a cytokine intended to activate immune responses. Selectivity was assessed using fresh patient GBM tissue samples, where SSE expression was detected in tumour cells but not in healthy brain tissue, according to the company. No dosing details, animal species, or group sizes were disclosed in the press release. Findings are limited to preclinical models, and no human data were reported. The company did not disclose the animal species used, sample sizes, statistical methods, or whether a formal control arm or standard-of-care comparator such as temozolomide was included in the study design. The press release does not describe dose-response data, pharmacokinetic or pharmacodynamic measurements, or the route of administration. The selectivity validation in patient tissue samples was conducted ex vivo and does not constitute in vivo human evidence. The underlying Nature publication (Koeber U, Matjusaitis M, Alfazema N et al., 2026), authored by researchers at the University of Edinburgh, UCL Cancer Institute, and the Royal Infirmary of Edinburgh, contains the full study methodology. Trogenix is preparing to begin patient dosing in Q2 2026 in the Phase I/II ADePT trial, assessing its first clinical-stage candidate TGX-007 for glioblastoma. TGX-007 is an AAV-delivered gene therapy utilizing a Synthetic Super-Enhancer (SSE) to drive selective, high-level therapeutic expression by targeting the core SOX2 and SOX9 transcriptional circuitry specific to glioblastoma cells. The SSE platform exploits tumour-specific transcriptional activity to drive selective payload expression, a conceptual departure from systemic immunotherapy approaches. GBM carries a five-year survival rate of approximately 5%, and no therapy has materially altered that figure since temozolomide was established as standard of care two decades ago. Preclinical findings may not translate to clinical outcomes. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website